Compare CSTL & NX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTL | NX |
|---|---|---|
| Founded | 2007 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 806.3M | 852.1M |
| IPO Year | 2019 | 2008 |
| Metric | CSTL | NX |
|---|---|---|
| Price | $18.95 | $20.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $45.50 | $28.00 |
| AVG Volume (30 Days) | 269.9K | ★ 290.9K |
| Earning Date | 05-06-2026 | 06-04-2026 |
| Dividend Yield | N/A | ★ 1.64% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $344,229,000.00 | ★ $1,837,641,000.00 |
| Revenue This Year | $2.42 | $4.26 |
| Revenue Next Year | $12.69 | $1.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 3.66 | ★ 43.81 |
| 52 Week Low | $14.59 | $11.04 |
| 52 Week High | $44.28 | $22.90 |
| Indicator | CSTL | NX |
|---|---|---|
| Relative Strength Index (RSI) | 25.76 | 54.49 |
| Support Level | $14.59 | $18.92 |
| Resistance Level | $25.06 | $22.64 |
| Average True Range (ATR) | 1.27 | 0.77 |
| MACD | -0.22 | -0.08 |
| Stochastic Oscillator | 2.71 | 56.33 |
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its four operating segments are North American Fenestration being the key revenue driver, European Fenestration, North American Cabinet Components, and Tyman. Geographically, it derives a majority of revenue from the United States.